Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
about
Fibroblast growth factor 23Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizationsPredictive Factors of One-Year Mortality in a Cohort of Patients Undergoing Urgent-Start HemodialysisFolate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease.Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatientsFibroblast growth factor 23: friend or foe in uremia?The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio Is a Useful Marker of Atherosclerosis in Early-Stage Chronic Kidney Disease.The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocolMineral metabolic abnormalities and mortality in dialysis patients.Associations of fibroblast growth factor 23 with parameters of phosphate metabolism in incident peritoneal dialysis patients.Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study.Hypophosphatemic rickets: unraveling the role of FGF23.Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis.The bone kidney axis.Fibroblast growth factor 23 and left ventricular mass index in maintenance hemodialysis patients: standard versus long nocturnal hemodialysis.Impact of hemodialysis, left ventricular mass and FGF-23 on myocardial mechanics in end-stage renal disease: a three-dimensional speckle tracking study.
P2860
Q26829294-E26DEA5E-9D14-46CD-AD5A-C7F39A95789CQ28286551-F5D31E0E-9042-49B6-B9AB-22EF6A1B92C6Q28468444-98B03090-0FF6-450C-B963-BE5699295730Q33734661-F58AF8E6-4E3E-4B28-AF20-3CBD41F7D3F5Q34988878-A576388D-09C7-4AB6-9DB4-C135AF99B1D5Q36068366-C476090C-19B5-4EEC-8F33-02C8D88CD297Q36098749-39F2273B-71A8-4C64-A0AF-BDCDFD14D14FQ36875566-010AE985-DB04-4815-92F0-37098E3FCC47Q36994038-F3EC2E6B-3A89-4E90-92D5-83A6D824978EQ37000712-91FCE959-9141-450E-A0D6-6119D3E0F63BQ37240698-958FF4E1-4011-4CC6-8D61-CD917E3D8CF0Q38045788-925EB034-A7F6-4E21-8062-CD8ECE2D34BCQ39056902-3B41B34C-DB0A-43B6-8C89-66D2791BC637Q41438552-BCDC56D3-04DD-499C-B68A-38843A260F27Q47817743-73FD7372-CCBB-4F04-A719-E55F372B605DQ50613899-07253955-A6B0-4F0B-8553-06F67556A6A5
P2860
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
@ast
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
@en
type
label
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
@ast
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
@en
prefLabel
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
@ast
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
@en
P2860
P1476
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
@en
P2093
Tamara Isakova
P2860
P304
P356
10.1097/MNH.0B013E328351A391
P577
2012-05-01T00:00:00Z